Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17614109 | 0.84 | BRD4 (0.33) | CTSSCTSKBRD4CASRLMNA | |
| SCHEMBL17599546 | 0.80 | MEN1 (0.45) | GAAHPGDTSHRLMNA | |
| SCHEMBL17599545 | 0.67 | ALDH1A1 (0.47) | GAAHPGDTSHRLMNAMAPK1 | |
| SCHEMBL17599525 | 0.66 | KMT2A (0.51) | GAAHPGDTSHRLMNAMAPK1 | |
| SCHEMBL27647476 | 0.65 | CYP2C9 (0.39) | CTSSCTSKGAAHPGD | |
| SCHEMBL9413687 | 0.65 | CACNA2D1 (0.47) | CTSSCTSKBRD4HPGDCASR | |
| SCHEMBL9413681 | 0.64 | BRD4 (0.44) | CTSSCTSKBRD4GAAHPGD | |
| SCHEMBL28857505 | 0.63 | RIPK1 (0.51) | CTSSCTSKTSHRLMNA | |
| SCHEMBL5654433 | 0.63 | RIPK1 (0.51) | CTSSCTSKTSHRLMNA | |
| SCHEMBL1915123 | 0.62 | SMN1; SMN2 (0.47) | CTSSCTSKGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998292-A1 | Naphthyl sulfonamide derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |